Drug Discovery World

DECEMBER 14, 2023

The new hub will become a part of the already thriving life sciences sector in the Glasgow area, most of which is centred around the university, the Cancer Research UK Scotland Institute and the BioCity cluster, making Glasgow and its surrounds one of the most important regions for drug discovery and development in the UK.

Drugs 75

Drugs Life Science Research Scientist 75

XTalks

JUNE 28, 2023

DMD is caused by the absence of dystrophin, a protein that helps maintain the integrity of muscle cells. Elevidys’ approval was based on data from a randomized trial that showed the therapy increased expression of the Elevidys micro-dystrophin protein, which was used as a surrogate endpoint, in DMD patients aged four to five years of age.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

XTalks

APRIL 13, 2021

synuclein, a protein involved in the formation of amyloid deposits in the brain characteristic of Parkinson’s disease and other neurodegenerative disorders, is also implicated in melanoma. The scientists found that the amyloid-forming protein is expressed at higher levels in melanoma cells than in normal healthy skin. In addition to ?-synuclein,

Research 98

Research Protein In-Vitro Gene Therapy 98

XTalks

FEBRUARY 27, 2023

The lysosomal storage disorder is caused by mutations in the MAN2B1 gene, which codes for lysosomal alpha-mannosidase, an enzyme that degrades glycoproteins (proteins attached to sugar residues). A lack of this enzyme results in a toxic build-up of mannose-containing sugars in the cells of the body, including the central nervous system (CNS).

FDA Approval 52

FDA Approval Life Science Containment Genetics 52

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

JUNE 16, 2021

The company’s candidate recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, is being evaluated in the PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19) Phase III trial, which has close to 30,000 participants across 119 states in the US and Mexico.

Vaccination 98

Vaccination Vaccine Protein Trials 98

XTalks

AUGUST 26, 2020

Researchers studied the proteins that act as chemical signals and conducted experiments to see how those signals were affecting the macrophages. They found a protein called Rspondin3, which is released at high levels during inflammatory injury. This protein plays a crucial role in macrophage programming.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

XTalks

AUGUST 6, 2020

Epidiolex is the only FDA-approved formulation that contains CBD derived from the cannabis plant. CBD is the most abundant non-psychoactive cannabinoid compound found in the cannabis plant, making up about 40 percent of the plant’s extract, which contains over 100 different cannabinoid compounds.

FDA Approval 64

FDA Approval Protein Containment Genetic Disease 64

XTalks

MAY 24, 2022

Now, Gilead has replaced the material of the container vial with aluminosilicate glass, proving it to be a good material for storage and compatibility. “We Lenacapavir is designed to act as an inhibitor of the HIV capsid protein, and it inhibits the virus at distinct stages (early and late) of its life cycle.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

The Pharma Data

DECEMBER 13, 2020

13, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. About SELLAS Life Sciences Group, Inc. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.

Life Science 52

Life Science Sales Licensing Licensing 52

Drug Discovery World

OCTOBER 20, 2022

Kawasaki King Skyfront is an R&D center with a focus on life science and environmental fields—and the realisation of open innovation projects. CELLINK Corporation, the Japanese subsidiary, was established in 2020 in Kansai, a region renowned for life sciences research facilities and corporations 3. .

Development 52

Development Drugs Life Science Marketing 52

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. The Huck Institutes of Life Sciences and the College of Agricultural Sciences provided support for studies performed at Penn State.

Vaccination 40

Vaccination Vaccine Protein Antibody 40

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Novasep provides cost-effective and sustainable manufacturing solutions for the life sciences industries. This press release contains certain forward-looking statements concerning Sensorion and its business.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

XTalks

MAY 4, 2023

Celiac disease is an autoimmune disorder that is triggered by the consumption of gluten, a protein found in barley, wheat and rye. When a person with celiac disease eats something that contains gluten, their immune system attacks their small intestine, damaging the lining and interfering with the absorption of nutrients from food.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

XTalks

DECEMBER 1, 2021

While researchers are still working out the epidemiological, clinical and molecular details of Omicron, so far, it is known that the variant is laden with up to 50 mutations, 30 or so of which are just in its outer spike (S) protein. The company said as a result, Omicron’s spike mutations do not impact the accuracy of its tests.

Gene 105

Gene Genome Genomics Genetics 105

XTalks

MAY 1, 2023

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. To date, over 200 mutations in the SOD1 gene have been associated with the development of ALS. How Does Qalsody Work?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

NOVEMBER 23, 2020

Under the partnership, Evotec will support Rappta’s programme of developing small molecule activators of the enzyme Protein Phosphatase 2A (“PP2A”), which downregulates multiple oncogenic signalling pathways responsible for driving cancer progression. Rappta has a strong scientific, management and commercial team.

Development 40

Development Protein Regulation Containment 40

XTalks

AUGUST 25, 2021

Of course, these factors were also aspects of their life that influenced the life expectancy, but researchers adjusted for this and took it into account in their analysis. Walnuts contain a number of essential nutrients, including protein, fiber, and magnesium and have a decent amount of omega 3 fatty acids.

Nurses 97

Nurses Containment Research Sales 97

The Pharma Data

JANUARY 18, 2021

Life Sciences Leader, Ernst & Young), Andrew Cheng (President and CEO, Akero Therapeutics), and Marshall Fordyce (President and CEO, Vera Therapeutics ). About Abingworth Abingworth is a leading transatlantic life sciences investment firm. “Dr. .” For more info, please visit abingworth.com.

Development 52

Development Life Science Protein Clinical Development 52

Pharma in Brief

DECEMBER 17, 2023

The Court found that this publication disclosed adalimumab and self-buffering protein formulations. However, the publication did not “plant a flag” in the claims at issue in the 458 Patent as, among other reasons, it only disclosed broad ranges of protein concentration and pH.

Antibody 52

Antibody Production Regulation Marketing 52

XTalks

JANUARY 27, 2021

Two independent pseudovirus neutralization (PsVN) assays were employed: one lentiviral-based and the other using a recombinant vesicular stomatitis virus (VSV), both bearing variants of the spike protein including those found in B.1.1.7 The two variants studied have mutations in the spike protein of SARS-CoV-2, with 17 mutations in B.1.1.7

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Drug Discovery World

JANUARY 9, 2024

However, government initiatives to contain healthcare costs, the sustained high cost of capital and global geopolitical disputes are negatively impacting investor appetites for the sector.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

XTalks

NOVEMBER 6, 2020

Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

JANUARY 28, 2022

Kimmtrak is a bispecific protein that contains a soluble T cell receptor fused to an anti-CD3 immune-effector function. The median treatment time is about 23 weeks (or 5.3 months), so the average cost per patient will be approximately $400,000.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

XTalks

NOVEMBER 23, 2020

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

MARCH 10, 2023

It is caused by a mutation in the FXN gene , which is responsible for the production of the protein frataxin. Usually diagnosed during adolescence ( 10-15 years ), Friedreich’s ataxia shortens life expectancy, causing the patient to be wheelchair bound within the first 10 to 20 years of diagnosis and most often leading to death.

FDA Approval 52

FDA Approval Engineer Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 8, 2020

The genetic material contains SARS-CoV-2 spike protein. The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees. The Phase 3 trial is being implemented as part of Operation Warp Speed.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals’ Adzynma, the first recombinant protein product for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare blood clotting disorder.

FDA Approval 59

FDA Approval Gene Therapy Gene Clinical Trials 59

The Pharma Data

JANUARY 18, 2021

About Chemerin and its receptor: The chemerin receptor (“CMKLR1”, also known as ChemR23) is a chemokine like G protein-coupled receptor (“GPCR”) expressed on select populations of cells, including inflammatory mediators (including macrophages, monocytes, plasmacytoid/myeloid dendritic cells and natural killer cells), as well as epithelial cells.

Life Science 40

Life Science Development Sales Drugs 40

XTalks

AUGUST 18, 2023

Izervay contains avacincaptad pegol sodium, an effective complement C5 inhibitor. Avacincaptad pegol can bind to and inhibit the complement protein C5, preventing the cleavage of C5 into C5a and C5b and significantly reducing membrane attack complex (MAC) formation. How Does Izervay Work?

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. GPS has previously been shown to invoke multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, suggestive of epitope spreading, and immunologically mediated cancer cell destruction, which are hallmarks of an effective cancer vaccine.

Life Science 52

Life Science Immune Response Trials Clinical Trials 52

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. for a pack of three pens, each containing 1.5 Jardiance brought in $2.06 billion for Eli Lilly and $6.23 billion for Boehringer Ingelheim. mL of 300 units/mL.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

APRIL 26, 2021

The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Oxford researchers developed the R21/MM malaria vaccine in collaboration with the Serum Institute of India and biotech company Novavax. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

XTalks

SEPTEMBER 15, 2020

Specifically, the vaccine contains human recombinant glutamate decarboxylase 65 (GAD65) protein conjugated to aluminum hydroxide (GAD-alum). The vaccine triggers an immune response against pro-inflammatory processes resulting from autoimmune attack of the pancreas – the inflammation helps to destroy the insulin-producing ?-islet

Vaccination 103

Vaccination Vaccine Insulin Trials 103

The Pharma Data

JANUARY 6, 2021

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. ak (2021-0003E).

Vaccination 52

Vaccination Vaccine Development Marketing 52

Pharmaceutical Technology

NOVEMBER 22, 2022

According to CEPI: “Achieving the 100 Days Mission would give the world a fighting chance of containing a future outbreak before it spreads to become a global pandemic.”. The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130